In an effort to predict HCC recurrence and based on the different scores based on pathological findings [7,31,32,33], the number of locoregional treatments before LT could be used as a surrogate for tumor aggressiveness and/or advanced HCC at presentation, such as AFP [34,35,36,37]. The gene discussed is AFP; the disease is hepatocellular carcinoma.